Mark Silver, MD
Endocrinology · Edmonds, WANPI 1790869352
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,317 of the $5,303 with a category attached, or 81.4%. It is spread thinly across 36 manufacturers, the largest accounting for just 13.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,792 and has fallen 82.0% since, to $322 in 2025.
Across 144 payments — averaging $36.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tandem Diabetes Care, Inc.$718
- Medtronic$669
- Novo Nordisk$419
- Dexcom, Inc.$394
- Lilly USA, LLC$332
- Sanofi-aventis U.S. LLC$327
- plus $2K from 30 others
What the payments were for
- Consulting fees$4008%
- Speaking & faculty fees$4859%
- Food & beverage$4,31781%
- Education$1012%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tandem Diabetes Care, Inc. | 14 | $718 |
| Medtronic(2 entities) | 10 | $669 |
| Novo Nordisk | 17 | $419 |
| Dexcom, Inc. | 10 | $394 |
| Lilly USA, LLC | 13 | $332 |
| Sanofi-aventis U.S. LLC | 11 | $327 |
| Chiesi USA, Inc. | 1 | $300 |
| AstraZeneca(2 entities) | 15 | $261 |
| Amgen | 6 | $237 |
| Sanofi | 1 | $185 |
| Johnson & Johnson | 3 | $177 |
| Xeris Pharmaceuticals, Inc. | 6 | $173 |
| Insulet Corporation | 4 | $141 |
| Boehringer Ingelheim | 2 | $127 |
| Radius Health, Inc. | 1 | $124 |
| Chiasma, Inc. | 1 | $95 |
| Bigfoot Biomedical Inc | 2 | $61 |
| Antares Pharma, Inc. | 2 | $55 |
| Recordati_rare_diseases_inc. | 2 | $54 |
| Merck | 4 | $53 |
| Ascensia Diabetes Care US Inc. | 2 | $45 |
| Abbott | 2 | $40 |
| Bayer | 1 | $35 |
| Esperion Therapeutics, Inc. | 1 | $29 |
| Corcept Therapeutics | 1 | $27 |
| Ultragenyx Pharmaceutical Inc. | 1 | $25 |
| AbbVie | 2 | $24 |
| Kowa Pharmaceuticals America, Inc. | 1 | $23 |
| Vifor Pharma, Inc. | 1 | $23 |
| EUSA Pharma (US) LLC | 1 | $22 |
| Halozyme Inc | 1 | $22 |
| Rhythm Pharmaceuticals, Inc. | 1 | $20 |
| Aegerion Pharmaceuticals, Inc. | 1 | $18 |
| Lifescan, Inc. | 1 | $16 |
| Novartis | 1 | $15 |
| Pfizer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- t:slim X2 insulin pump$400
- MYCAPSSA$300
- TOUJEO$185
- MINIMED 780G$149
- Ozempic$125
- INVOKANA$124
- Tymlos$124
- TZIELD$124
- JARDIANCE$122
- Minimed 670G System$121
- DEXCOM G7 GSS (161)$112
- Repatha$104
How this compares
Too few endocrinology providers in Washingtonto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 160 | $213,419 |
| JardianceEmpagliflozin | 140 | $183,880 |
| OzempicSemaglutide | 85 | $129,693 |
| Tresiba Flextouch U-200Insulin Degludec | 86 | $121,818 |
| Somatuline DepotLanreotide Acetate | 13 | $99,265 |
| FarxigaDapagliflozin Propanediol | 73 | $95,694 |
| TrulicityDulaglutide | 56 | $95,070 |
| Tresiba Flextouch U-100Insulin Degludec | 113 | $79,786 |
| Humalog Kwikpen U-200Insulin Lispro | 26 | $77,102 |
| VascepaIcosapent Ethyl | 39 | $37,347 |
| Bydureon BciseExenatide Microspheres | 24 | $36,671 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $24,395 |
| Novolog FlexpenInsulin Aspart | 47 | $22,230 |
| XyostedTestosterone Enanthate | 19 | $22,151 |
| Humalog Kwikpen U-100Insulin Lispro | 41 | $14,589 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Baqsimi | $332 | $323,527259 claims |
| Boehringer IngelheimJardiance | $127 | $183,880140 claims |
| Novo NordiskOzempic, Fiasp, Novolog | $419 | $144,841125 claims |
| AstraZenecaFarxiga | $261 | $95,69473 claims |
| Antares Pharma, Inc.Xyosted | $55 | $22,15119 claims |
| AbbVieSynthroid | $24 | $13,392108 claims |
| PfizerLevoxyl | $15 | $12,424307 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few endocrinology providers in Washingtonon file to place this against a meaningful peer group, so we don't.
Other endocrinology in Edmonds
- Nadia HameedBellevue$2K
- Hou Hsien ChiangSeattle$0
- Jeremy ChoySeattle$0
- Anh TranEverett$0
- Shannon HeitritterSeattle$0
- Wei HaoSeattle$0
- Jessica LucierVancouver$0
- Robert MurraySeattle$0
- Laura BoveeSeattle$0
- Isaye BartonSeattle$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.